Altium Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Altium Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-127,000	Closed	-$15.4M	–	62
2024 Q4	$15.4M	Sell	127,000 -43,000	-25%	-$5.27M	4.38%	3
2024 Q3	$21.2M	Buy	170,000 +88,100	+108%	+$12.2M	6.25%	3
2024 Q2	$12.9M	Buy	+81,900	New	+$10.5M	5.28%	5
2023 Q4	–	Sell	-29,300	Closed	-$3.55M	–	87
2023 Q3	$3.55M	Buy	29,300 +1,300	+5%	+$147K	1.85%	21
2023 Q2	$3.21M	Buy	+28,000	New	+$3.61M	2.43%	16

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Altium Capital Management's SRPT Position: Q1 2025 in Review

Altium Capital Management sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 127,000 shares — an estimated $15.4M sold.

Altium Capital Management first reported a position in SRPT in Q2 2023 and held it in 5 quarters. The position peaked at $21.2M in Q3 2024. 431 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Altium Capital Management reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Altium Capital Management sold 127,000 Sarepta Therapeutics shares in Q1 2025, an estimated $15.4M.
Altium Capital Management first reported a position in Sarepta Therapeutics in Q2 2023 and held it in 5 quarters.
Altium Capital Management's Sarepta Therapeutics position peaked at $21.2M in Q3 2024.
431 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Altium Capital Management's 13F filing for Q1 2025, filed 9 May 2025.